Evidence map›Paper›PMID 41773242›Full record

ReviewInternational journal of nanomedicine2026

Exosomes as Pivotal Mediators of Tumor-Immune Communication: Implications for Immunotherapy and Liquid Biopsy.

Menglin Wei, Dongli Wang, Wenrong Xu, Xueyan Zang, Jiajia Jiang

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Menglin Wei *Aoyang Institute of Cancer, Center of Clinical Laboratory, Affiliated Aoyang Hospital of Jiangsu University, Suzhou, Jiangsu, 215600, People's Republic of China.
Dongli Wang *Aoyang Institute of Cancer, Center of Clinical Laboratory, Affiliated Aoyang Hospital of Jiangsu University, Suzhou, Jiangsu, 215600, People's Republic of China.
Wenrong XuAoyang Institute of Cancer, Center of Clinical Laboratory, Affiliated Aoyang Hospital of Jiangsu University, Suzhou, Jiangsu, 215600, People's Republic of China.
Xueyan ZangAoyang Institute of Cancer, Center of Clinical Laboratory, Affiliated Aoyang Hospital of Jiangsu University, Suzhou, Jiangsu, 215600, People's Republic of China.
Jiajia JiangAoyang Institute of Cancer, Center of Clinical Laboratory, Affiliated Aoyang Hospital of Jiangsu University, Suzhou, Jiangsu, 215600, People's Republic of China.ORCID 0000-0003-2139-4240

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exosomes are membrane-bound vesicles secreted by almost all types of cells, including but not limited to immune cells, neurons, epithelial cells, and cancer cells. Exosomes carry DNA, RNA, lipids, metabolites, as well as cytoplasmic and cell surface proteins. Their role in cancer progression is dynamic and is related to the type of cancer, genetics, and stage. At the same time, exosomes have attracted widespread attention as key mediators of intercellular communication in the tumor immune microenvironment (TME). This comprehensive review delineates the pleiotropic roles of exosomes in tumor immunobiology, emphasizing their bimodal capacity to either foster immunosuppression or potentiate antitumor immunity. We systematically synthesize recent advancements in exosome-based immunotherapeutic regimens, with particular emphasis on their synergistic efficacy when integrated with established modalities, namely immune checkpoint blockade and adoptive cellular therapy. Furthermore, we critically appraise emergent technologies for exosome isolation and characterization, underscoring their transformative implications for liquid biopsy platforms in real-time immune surveillance and the development of predictive biomarkers. This review posits exosome-centric strategies as a paradigm-shifting frontier in precision immuno-oncology, furnishing innovative remedies for recalcitrant therapeutic hurdles and propelling the advancement of personalized oncology care.

Indexed as

ExosomesImmunotherapyNeoplasmsAnimalsBiomarkers, TumorCell CommunicationHumansLiquid BiopsyTumor MicroenvironmentBiomarkers, Tumorbiomarkercancer immunotherapyexosomeliquid biopsytumor immune microenvironment

Identifiers

PMID41773242
PMCPMC12949809

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.